Cargando…

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

BACKGROUND: Multiple targeted immunomodulators (TIMs) for psoriatic arthritis (PsA) treatment are available, but limited studies have directly compared these agents. This study indirectly compared the efficacy of TNF-α, interleukins, and phosphodiesterase-4 inhibitors for treatment of active PsA. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Elaine Husni, M., Betts, Keith A., Song, Yan, Singh, Rakesh, Griffith, Jenny, Beppu, Marci, Zhao, Jing, Ganguli, Arijit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390550/ https://www.ncbi.nlm.nih.gov/pubmed/30886954 http://dx.doi.org/10.1186/s41927-018-0011-1

Ejemplares similares

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US
por: Strand, Vibeke, et al.
Publicado: (2016)

Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
por: Betts, Keith A., et al.
Publicado: (2016)

Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study
por: Husni, M. Elaine, et al.
Publicado: (2018)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
por: Song, Yan, et al.
Publicado: (2019)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis
por: Lucke, Michael, et al.
Publicado: (2016)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
por: Strand, Vibeke, et al.
Publicado: (2012)

Cost per responder of TNF-α therapies in Germany
por: Gissel, Christian, et al.
Publicado: (2013)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
por: Raciborski, Filip, et al.
Publicado: (2016)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
por: Coates, Laura C., et al.
Publicado: (2022)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study
por: Aletaha, Daniel, et al.
Publicado: (2020)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
por: Helliwell, Philip, et al.
Publicado: (2014)

Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis
por: Shafrin, Jason, et al.
Publicado: (2016)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
por: Strand, Vibeke, et al.
Publicado: (2018)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
por: Gladman, Dafna, et al.
Publicado: (2020)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
por: Helliwell, Philip, et al.
Publicado: (2018)

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study
por: Kavanaugh, Arthur, et al.
Publicado: (2017)

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

JAK inhibition for treatment of psoriatic arthritis in Down syndrome
por: Pham, Andrew T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ombohiie1fppkv786gmursjpib